Olema Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2021-09-01

Reporting Person: Bohen Sean (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-01	Common Stock	M	871	$4.824	Acquired	55145	Direct
2021-09-01	Common Stock	S	871	$30.05	Disposed	54274	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Stock Option (Right to Buy)	$4.824	M	871	Disposed	2030-11-18	Common Stock (871)	Direct

Footnotes

F1: Includes 2,625 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021.

F2: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F3: The weighted average sale price for the transaction reported was $30.05, and the range of prices were between $30.01 and $30.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F4: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable.